Boston, MA, August 28, 2016 — On Monday, September 19, 2016, Xtalks will host a complimentary webinar discussing the assessment of tumor burden and clinical benefit in immunotherapy clinical trials. Featured speakers include Dr. Klaus Noever, Senior Director of Medical Affairs at WorldCare …
Director of Operations, Ophthalmology
Jeff oversees the operations of the ophthalmic team at WorldCare Clinical. Jeff has served as Director of Operations at Digital Angiography Reading Center (DARC) for more than 13 years, helping to build the first all-digital ophthalmic reading center for clinical trials. Jeff has more than 20 years of experience working at Fortune 100 companies such as Credit Suisse First Boston and Colgate Palmolive. Jeff joined WCC in 2021 with the combination of DARC and WCC.
Medical Director
Dr. Slakter is an internationally recognized retinal disease specialist with over 30 years of experience in clinical practice. He created the Digital Angiography Reading Center (DARC), which is one of the largest centers for image evaluation for clinical trials of posterior segment disease with over 1,600 certified clinical sites in over 70 countries worldwide, serving as a key resource for industry-sponsored studies of new treatments for retinal disorders. Dr. Slakter is also a Clinical Professor of Ophthalmology at NYU School of Medicine and has published more than 100 papers and book chapters. Dr. Slakter serves as the Chief Executive Officer of Orphion Therapeutics, Inc., a gene therapy company focused on developing new treatments to meet unmet needs for rare genetic diseases. Dr. Slakter is WCC’s Medical Director for Ophthalmology and has worked with WCC since the combination of DARC and WCC in 2021.
Vice President, Program Management
Chief Scientific Officer
Dr. Walovitch is Chief Scientific Officer of WCC, which he joined as Chief Medical Officer in January 2009. Prior to joining WCC, he served as the Senior Vice President of clinical research at Acusphere, Inc., Vice President of Preclinical and Clinical Research at Epix Medical, and held various positions as Research Pharmacologist and Project Clinician in the Imaging Agent Group at the DuPont Merck Pharmaceutical Company. He completed his postdoctoral fellowship at the National Institute on Drug Abuse’s Addiction Research Center in the Neurochemistry section. Dr. Walovitch has a Doctorate in Pharmacology from the University of Illinois Medical Center and a Bachelor’s degree in biology from the University of Illinois. He is an author of more than 100 peer-reviewed publications, mostly in the field of medical imaging.
Chief Executive Officer
